NCT07218770

A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants

A Phase 1/2a Study of REGN7041 (Anti-CD3 Monoclonal Antibody) in Participants With Active Noninfectious Uveitis Affecting the Posterior Segment

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: Regeneron Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is researching an experimental drug called REGN7041 (also referred to as "study drug"). The study is focused on patients who have active inflammation inside of the eye without any signs of infection. The aim of the study is to see how safe and tolerable the study drug is. This is the first time the study drug is being tested in humans. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood and the fluid in the eye at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Conditions

• Active Noninfectious Uveitis Affecting the Posterior Segment

Interventions

Type	Name	Description
DRUG	REGN7041	Administered as per the protocol

Timeline

• Start date: 2025-12-17
• Primary completion: 2028-06-28
• Completion: 2028-06-28
• First posted: 2025-10-20
• Last updated: 2026-03-24

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study